4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-010827
CHIEF FINANCIAL OFFICER sold 14,000 shares at an average $24.72 ($346,149)
- CHIEF FINANCIAL OFFICER acquired 14,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Hohl Benjamin · CHIEF FINANCIAL OFFICER
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-04-11 | Exercise or conversion : show line 1 in the form 10b5-1 | +14,000 | $2.48 | $34,720 | 14,000 | D |
| 2024-04-11 | Sale : show line 2 in the form 10b5-1 | −3,777 | $23.88 | $90,179 | 10,223 | D |
| 2024-04-11 | Sale : show line 3 in the form 10b5-1 | −10,223 | $25.04 | $255,970 | 0 | D |
| Open-market sales · 14,000 sh · avg $24.72 · $346,149 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-04-11 | Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (right to buy) | −14,000 | 225,370 | D |
Loading xslF345X05/form4-04152024_110419.xml…